Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001848 | 0.96 | CYP4A11 (0.44) | CYP4A11LOXL2CYP4F2ALDH1A1MAPT | |
| SCHEMBL6138542 | 0.90 | CYP4Z1 (0.41) | CYP4A11LOXL2CYP4F2ALDH1A1MAPT | |
| SCHEMBL9442229 | 0.90 | POLB (0.45) | CYP4A11LOXL2CYP4F2ALDH1A1MAPT | |
| SCHEMBL2294361 | 0.84 | CYP4A11 (0.43) | CYP4A11LOXL2CYP4F2ALDH1A1MAPT | |
| SCHEMBL3594773 | 0.82 | SMN1; SMN2 (0.44) | CYP4A11CYP4F2MAPTGAAKDM4E | |
| SCHEMBL3016468 | 0.82 | CYP4A11 (0.53) | CYP4A11LOXL2CYP4F2ALDH1A1MAPT | |
| SCHEMBL3596235 | 0.81 | LOXL2 (0.47) | CYP4A11LOXL2CYP4F2ALDH1A1MAPT | |
| SCHEMBL3595029 | 0.81 | CYP4A11 (0.48) | CYP4A11LOXL2CYP4F2ALDH1A1MAPT | |
| SCHEMBL9442211 | 0.81 | FOLH1 (0.53) | CYP4A11LOXL2CYP4F2ALDH1A1MAPT | |
| SCHEMBL3596584 | 0.79 | NFE2L2 (0.42) | ALDH1A1MAPTKDM4EHSD17B10RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674825-B2 | Dicarboxylic acid derivatives with pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2010-03-09 | — | — | US | disclosed |
| US-20080058314-A1 | Novel dicarboxylic acid derivatives with pharmaceutical properties | BAYER AKTIENGESELLSCHAFT | 2008-03-06 | — | — | US | disclosed |
| EP-1655280-A1 | Dicarboxylic acid derivates with pharmaceutical properties | Bayer HealthCare AG (DE) | 2006-05-10 | — | — | EP | disclosed |
| EP-1216223-B1 | NOVEL DICARBOXYLIC ACID DERIVATIVES WITH PHARMACEUTICAL PROPERTIES | BAYER HEALTHCARE AG (DE) | 2005-11-09 | — | — | EP | disclosed |
| US-6864287-B1 | Derivatives of dicarboxylic acid having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-08 | — | — | US | disclosed |
| EP-1216222-A2 | NOVEL DERIVATIVES OF DICARBOXYLIC ACID HAVING PHARMACEUTICAL PROPERTIES | Bayer Aktiengesellschaft (DE) | 2002-06-26 | — | — | EP | disclosed |
| EP-1216223-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES WITH PHARMACEUTICAL PROPERTIES | Bayer Aktiengesellschaft (DE) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001019778-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES WITH PHARMACEUTICAL PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
| WO-2001019776-A2 | NOVEL DERIVATIVES OF DICARBOXYLIC ACID HAVING PHARMACEUTICAL PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
| US-5221760-A | Intermediates, leukotriene antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 1993-06-22 | — | — | US | disclosed |
| US-5159097-A | An arylphosphorous compound as chemical intermediate | BAYER AKTIENGESELLSCHAFT (DE) | 1992-10-27 | — | — | US | disclosed |
| EP-0341551-B1 | ALKENOIC ACID DERIVATIVES | BAYER AG (DE) | 1992-04-01 | — | — | EP | disclosed |
| US-5041638-A | Leucotriene antagonist; treatment of respiratory system disorders, cardiovascular disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1991-08-20 | — | — | US | disclosed |
| EP-0341551-A1 | Alkenoic acid derivatives | BAYER AG (DE) | 1989-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058314-A1 | Novel dicarboxylic acid derivatives with pharmaceutical properties | PC, GOT2, SDHA | CYP4A11 716/4885LOXL2 3827/4885CYP4F2 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.